Avalon Pharma (Middle East Pharmaceutical) (4016.SR)

EPS in 2026 (TTM): HK$4.71

According to Avalon Pharma (Middle East Pharmaceutical)'s latest financial reports the company's current EPS (TTM) is HK$4.71. In 2025 the company made an earnings per share (EPS) of HK$5.80 an increase over its 2024 EPS that were of HK$4.77.

EPS history for Avalon Pharma (Middle East Pharmaceutical) from 2023 to 2026

Annual EPS

Year	EPS	Change
2026 (TTM)	HK$4.71	-18.89%
2025	HK$5.80	21.69%
2024	HK$4.77	21.02%
2023	HK$3.94

What is the market capitalization of a company?

The market capitalization sometimes referred as Marketcap, is the value of a publicly listed company.
In most cases it can be easily calculated by multiplying the share price with the amount of outstanding shares.

DISCLAIMER

CompaniesMarketCap is not associated in any way with CoinMarketCap.com
Stock prices are delayed, the delay can range from a few minutes to several hours.
Company logos are from the CompaniesLogo.com logo database and belong to their respective copyright holders. Companies Marketcap displays them for editorial purposes only.

Contact

For inquiries or if you want to report a problem write to hello@8marketcap.com

Links

- Privacy policy

- Terms and conditions

EPS for Avalon Pharma (Middle East Pharmaceutical) (4016.SR)